Induction of cell fusion/apoptosis in anaplastic thyroid carcinoma in orthotopic mouse model by urokinase-specific oncolytic Sendai virus

Yoshihiro Miyagawa, Koji Araki, Taku Yamashita, Shingo Tanaka, Yuya Tanaka, Masayuki Tomifuji, Yasuji Ueda, Yoshikazu Yonemitsu, Hideaki Shimada, Akihiro Shiotani

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: This study was designed to assess the therapeutic effect of urokinase-targeted recombinant oncolytic Sendai virus, termed “BioKnife,” on anaplastic thyroid carcinoma (ATC). Methods: Urokinase activity was investigated in human ATC cell lines, and BioKnife cytotoxicity against the cell lines was evaluated in vitro. Orthotopic mouse models of ATC were treated with three intratumoral injections of BioKnife, control virus, or phosphate-buffered saline (PBS) and were observed daily until >20% weight loss occurred. Results: All three ATC cell lines showed a high level of urokinase activity. BioKnife induced urokinase-dependent cell fusion and cytotoxicity in all cell lines. Orthotopic models treated with BioKnife showed significantly prolonged survival compared with models treated with control virus or PBS (BioKnife 41.6 ± 15.0, control virus 17.0 ± 2.9, PBS 17.7 ± 6.3 days). Conclusions: BioKnife exerted therapeutic effects in orthotopic ATC mouse models. Thus, BioKnife represents a possible treatment option for ATC.

Original languageEnglish
Pages (from-to)2873-2882
Number of pages10
JournalHead and Neck
Volume41
Issue number9
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Oncolytic Viruses
Sendai virus
Cell Fusion
Urokinase-Type Plasminogen Activator
Apoptosis
Cell Line
Phosphates
Therapeutic Uses
Viruses
Anaplastic Thyroid Carcinoma
Weight Loss
Injections
Survival

All Science Journal Classification (ASJC) codes

  • Otorhinolaryngology

Cite this

Miyagawa, Y., Araki, K., Yamashita, T., Tanaka, S., Tanaka, Y., Tomifuji, M., ... Shiotani, A. (2019). Induction of cell fusion/apoptosis in anaplastic thyroid carcinoma in orthotopic mouse model by urokinase-specific oncolytic Sendai virus. Head and Neck, 41(9), 2873-2882. https://doi.org/10.1002/hed.25769

Induction of cell fusion/apoptosis in anaplastic thyroid carcinoma in orthotopic mouse model by urokinase-specific oncolytic Sendai virus. / Miyagawa, Yoshihiro; Araki, Koji; Yamashita, Taku; Tanaka, Shingo; Tanaka, Yuya; Tomifuji, Masayuki; Ueda, Yasuji; Yonemitsu, Yoshikazu; Shimada, Hideaki; Shiotani, Akihiro.

In: Head and Neck, Vol. 41, No. 9, 01.01.2019, p. 2873-2882.

Research output: Contribution to journalArticle

Miyagawa, Y, Araki, K, Yamashita, T, Tanaka, S, Tanaka, Y, Tomifuji, M, Ueda, Y, Yonemitsu, Y, Shimada, H & Shiotani, A 2019, 'Induction of cell fusion/apoptosis in anaplastic thyroid carcinoma in orthotopic mouse model by urokinase-specific oncolytic Sendai virus', Head and Neck, vol. 41, no. 9, pp. 2873-2882. https://doi.org/10.1002/hed.25769
Miyagawa, Yoshihiro ; Araki, Koji ; Yamashita, Taku ; Tanaka, Shingo ; Tanaka, Yuya ; Tomifuji, Masayuki ; Ueda, Yasuji ; Yonemitsu, Yoshikazu ; Shimada, Hideaki ; Shiotani, Akihiro. / Induction of cell fusion/apoptosis in anaplastic thyroid carcinoma in orthotopic mouse model by urokinase-specific oncolytic Sendai virus. In: Head and Neck. 2019 ; Vol. 41, No. 9. pp. 2873-2882.
@article{ce44138f6caa4177a321ce7ba63684dc,
title = "Induction of cell fusion/apoptosis in anaplastic thyroid carcinoma in orthotopic mouse model by urokinase-specific oncolytic Sendai virus",
abstract = "Background: This study was designed to assess the therapeutic effect of urokinase-targeted recombinant oncolytic Sendai virus, termed “BioKnife,” on anaplastic thyroid carcinoma (ATC). Methods: Urokinase activity was investigated in human ATC cell lines, and BioKnife cytotoxicity against the cell lines was evaluated in vitro. Orthotopic mouse models of ATC were treated with three intratumoral injections of BioKnife, control virus, or phosphate-buffered saline (PBS) and were observed daily until >20{\%} weight loss occurred. Results: All three ATC cell lines showed a high level of urokinase activity. BioKnife induced urokinase-dependent cell fusion and cytotoxicity in all cell lines. Orthotopic models treated with BioKnife showed significantly prolonged survival compared with models treated with control virus or PBS (BioKnife 41.6 ± 15.0, control virus 17.0 ± 2.9, PBS 17.7 ± 6.3 days). Conclusions: BioKnife exerted therapeutic effects in orthotopic ATC mouse models. Thus, BioKnife represents a possible treatment option for ATC.",
author = "Yoshihiro Miyagawa and Koji Araki and Taku Yamashita and Shingo Tanaka and Yuya Tanaka and Masayuki Tomifuji and Yasuji Ueda and Yoshikazu Yonemitsu and Hideaki Shimada and Akihiro Shiotani",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/hed.25769",
language = "English",
volume = "41",
pages = "2873--2882",
journal = "Head and Neck Surgery",
issn = "1043-3074",
publisher = "John Wiley and Sons Inc.",
number = "9",

}

TY - JOUR

T1 - Induction of cell fusion/apoptosis in anaplastic thyroid carcinoma in orthotopic mouse model by urokinase-specific oncolytic Sendai virus

AU - Miyagawa, Yoshihiro

AU - Araki, Koji

AU - Yamashita, Taku

AU - Tanaka, Shingo

AU - Tanaka, Yuya

AU - Tomifuji, Masayuki

AU - Ueda, Yasuji

AU - Yonemitsu, Yoshikazu

AU - Shimada, Hideaki

AU - Shiotani, Akihiro

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: This study was designed to assess the therapeutic effect of urokinase-targeted recombinant oncolytic Sendai virus, termed “BioKnife,” on anaplastic thyroid carcinoma (ATC). Methods: Urokinase activity was investigated in human ATC cell lines, and BioKnife cytotoxicity against the cell lines was evaluated in vitro. Orthotopic mouse models of ATC were treated with three intratumoral injections of BioKnife, control virus, or phosphate-buffered saline (PBS) and were observed daily until >20% weight loss occurred. Results: All three ATC cell lines showed a high level of urokinase activity. BioKnife induced urokinase-dependent cell fusion and cytotoxicity in all cell lines. Orthotopic models treated with BioKnife showed significantly prolonged survival compared with models treated with control virus or PBS (BioKnife 41.6 ± 15.0, control virus 17.0 ± 2.9, PBS 17.7 ± 6.3 days). Conclusions: BioKnife exerted therapeutic effects in orthotopic ATC mouse models. Thus, BioKnife represents a possible treatment option for ATC.

AB - Background: This study was designed to assess the therapeutic effect of urokinase-targeted recombinant oncolytic Sendai virus, termed “BioKnife,” on anaplastic thyroid carcinoma (ATC). Methods: Urokinase activity was investigated in human ATC cell lines, and BioKnife cytotoxicity against the cell lines was evaluated in vitro. Orthotopic mouse models of ATC were treated with three intratumoral injections of BioKnife, control virus, or phosphate-buffered saline (PBS) and were observed daily until >20% weight loss occurred. Results: All three ATC cell lines showed a high level of urokinase activity. BioKnife induced urokinase-dependent cell fusion and cytotoxicity in all cell lines. Orthotopic models treated with BioKnife showed significantly prolonged survival compared with models treated with control virus or PBS (BioKnife 41.6 ± 15.0, control virus 17.0 ± 2.9, PBS 17.7 ± 6.3 days). Conclusions: BioKnife exerted therapeutic effects in orthotopic ATC mouse models. Thus, BioKnife represents a possible treatment option for ATC.

UR - http://www.scopus.com/inward/record.url?scp=85064173797&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064173797&partnerID=8YFLogxK

U2 - 10.1002/hed.25769

DO - 10.1002/hed.25769

M3 - Article

AN - SCOPUS:85064173797

VL - 41

SP - 2873

EP - 2882

JO - Head and Neck Surgery

JF - Head and Neck Surgery

SN - 1043-3074

IS - 9

ER -